ProfileGDS5678 / 1416048_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 90% 90% 91% 90% 89% 91% 90% 90% 91% 91% 92% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2777391
GSM967853U87-EV human glioblastoma xenograft - Control 27.316290
GSM967854U87-EV human glioblastoma xenograft - Control 37.1823290
GSM967855U87-EV human glioblastoma xenograft - Control 47.6914491
GSM967856U87-EV human glioblastoma xenograft - Control 57.2635690
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7428389
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2168191
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2207490
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2536390
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.3397791
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.3067191
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5959992
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3814191
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2562490